The Emperor’s New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?

Monoclonal Antibodies for Migraine Prevention

(2018) Elizabeth W. Loder et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

(2016) Tiffini Voss et al.   CEPHALALGIA

Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations

(2016) Sander Greenland et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Telcagepant—almost gone, but not to be forgotten (invited editorial related to Ho et al., 2015)

(2015) P Christopher H Gottschalk   CEPHALALGIA

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

(2014) T. W. Ho et al.   NEUROLOGY

BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

(2013) Ronald Marcus et al.   CEPHALALGIA

Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists in the Treatment of Migraine

(2010) Paul L. Durham et al.   CNS DRUGS

Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974)

(2009) Simon R. Sinclair et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

(2008) Tony W Ho et al.   LANCET